Background Lymphovascular invasion (LVI) status facilitates the selection of optimal therapeutic strategy for breast cancer patients, but in clinical practice LVI status is determined in pathological specimens after resection. Purpose To explore the use of dynamic contrast‐enhanced (DCE)‐magnetic resonance imaging (MRI)‐based radiomics for preoperative prediction of LVI in invasive breast cancer. Study Type Prospective. Population Ninety training cohort patients (22 LVI‐positive and 68 LVI‐negative) and 59 validation cohort patients (22 LVI‐positive and 37 LVI‐negative) were enrolled. Field Strength/Sequence 1.5 T and 3.0 T, T1‐weighted DCE‐MRI. Assessment Axillary lymph node (ALN) status for each patient was evaluated based on MR images (defined as MRI ALN status), and DCE semiquantitative parameters of lesions were calculated. Radiomic features were extracted from the first postcontrast DCE‐MRI. A radiomics signature was constructed in the training cohort with 10‐fold cross‐validation. The independent risk factors for LVI were identified and prediction models for LVI were developed. Their prediction performances and clinical usefulness were evaluated in the validation cohort. Statistical Tests Mann–Whitney U‐test, chi‐square test, kappa statistics, least absolute shrinkage and selection operator (LASSO) regression, logistic regression, receiver operating characteristic (ROC) analysis, DeLong test, and decision curve analysis (DCA). Results Two radiomic features were selected to construct the radiomics signature. MRI ALN status (odds ratio, 10.452; P < 0.001) and the radiomics signature (odds ratio, 2.895; P = 0.031) were identified as independent risk factors for LVI. The value of the area under the curve (AUC) for a model combining both (0.763) was higher than that for MRI ALN status alone (0.665; P = 0.029) and similar to that for the radiomics signature (0.752; P = 0.857). DCA showed that the combined model added more net benefit than either feature alone. Data Conclusion The DCE‐MRI‐based radiomics signature in combination with MRI ALN status was effective in predicting the LVI status of patients with invasive breast cancer before surgery. Level of Evidence: 1 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019;50:847–857.
Purpose: To develop a radiomics nomogram based on computed tomography (CT) images that can help differentiate lung adenocarcinomas and granulomatous lesions appearing as sub-centimeter solid nodules (SCSNs). Materials and methods: The records of 214 consecutive patients with SCSNs that were surgically resected and histologically confirmed as lung adenocarcinomas (n = 112) and granulomatous lesions (n = 102) from 2 medical institutions between October 2011 and June 2019 were retrospectively analyzed. Patients from center 1 ware enrolled as training cohort (n = 150) and patients from center 2 were included as external validation cohort (n = 64), respectively. Radiomics features were extracted from non-contrast chest CT images preoperatively. The least absolute shrinkage and selection operator (LASSO) regression model was used for radiomics feature extraction and radiomics signature construction. Clinical characteristics, subjective CT findings, and radiomics signature were used to develop a predictive radiomics nomogram. The performance was examined by assessment of the area under the receiver operating characteristic curve (AUC). Results: Lung adenocarcinoma was significantly associated with an irregular margin and lobulated shape in the training set (p = 0.001, < 0.001) and external validation set (p = 0.016, = 0.018), respectively. The radiomics signature consisting of 22 features was significantly associated with lung adenocarcinomas of SCSNs (p < 0.001). The radiomics nomogram incorporated the radiomics signature, gender and lobulated shape. The AUCs of combined model in the training and external validation dataset were 0.885 (95% confidence interval [CI]: 0.823-0.931), 0.808 (95% CI: 0.690-0.896), respectively. Decision curve analysis (DCA) demonstrated that the radiomics nomogram was clinically useful.
Background Morphological findings showed poor accuracy in differentiating angiomyolipoma without visible fat (AMLwvf) from renal cell carcinoma (RCC). Purpose To determine the performance of a machine learning classifier in differentiating AMLwvf from different subtypes of RCC based on whole-tumor slices of CT images. Material and Methods In this retrospective study, 171 pathologically proven renal masses were collected from a single institution. Texture features were extracted from whole-tumor images in three phases including the pre-contrast (PCP), corticomedullary (CMP), and nephrographic (NP) phases. A support vector machine with the recursive feature elimination method based on fivefold cross-validation (SVM-RFECV) with the synthetic minority oversampling technique (SMOTE) was utilized to establish classifiers for differentiating AMLwvf from all subtypes of RCC (all-RCC), clear cell RCC (ccRCC), and non-ccRCC. The performances of the classifiers based on three-phase and single-phase images were compared with each other and morphological interpretations. Results A machine learning classifier achieved the best performance in differentiating AMLwvf from all-RCC, ccRCC, and non-ccRCC. The performance of the best machine learning classifier for differentiating AMLwvf from all-RCC (area under the curve [AUC] = 0.96) and ccRCC (AUC = 0.97) was higher than that for differentiating AMLwvf from non-ccRCC (AUC = 0.89); morphological interpretations achieved lower performance for differentiating AMLwvf from all-RCC (AUC = 0.67), ccRCC (AUC = 0.68), and non-ccRCC (AUC = 0.64). Conclusion Machine learning can be a useful non-invasive technique for differentiating AMLwvf from all-RCC, ccRCC, and non-ccRCC, and it can be more accurate than morphological interpretation by radiologists.
In the present study, we aimed to construct a radiomics model using contrast-enhanced computed tomography (CT) to predict the pathological invasiveness of thymic epithelial tumors (TETs). We retrospectively reviewed the records of 179 consecutive patients (89 females) with histologically confirmed TETs from two hospitals. The 82 low-and 97 high-risk TETs were assigned to training (90 tumors), internal validation (49 tumors) and external validation (40 tumors) cohorts. Radiomics features extracted from preoperative contrast-enhanced chest CT were selected using least absolute shrinkage and selection operator logistic regression. Three prediction models were developed using multivariate logistic regression analysis. Their performance and clinical utility were assessed using receiver operating characteristic curves and the DeLong test, respectively. Eight radiomics features with non-zero coefficients were used to develop a radiomics score, which significantly differed between low-and high-risk TETs (P<0.001). The subjective finding, infiltration, was independently associated with high-risk TETs. Prediction models based on infiltration alone, the radiomics signature alone, and both these parameters showed diagnostic accuracies of 72.2% [area under curve (AUC), 0.731; 95% confidence interval (CI): 0.627-0.819; sensitivity, 85.7%; specificity, 60.4%], 88.9% (AUC, 0.944; 95% CI: 0.874-0.981; sensitivity, 92.9%; specificity, 85.4%), and 90.0% (AUC, 0.953; 95% CI: 0.887-0.987; sensitivity, 92.9%; specificity, 87.5%), respectively. Decision-curve analysis showed that the combined model added more net benefit than the single-parameter models. In conclusion, a radiomics signature based on contrast-enhanced CT has the potential to differentiate between low-and high-risk TETs. The model incorporating the radiomics signature and subjective finding may facilitate the individualized, preoperative prediction of the pathological invasiveness of TETs.
Background: Comparisons of hepatic epithelioid hemangioendothelioma (HEHE), hepatic hemangioma, and hepatic angiosarcoma (HAS) have rarely been reported. The purpose of our study was to analyze the clinical and magnetic resonance imaging (MRI) findings of these conditions. Methods: A total of 57 patients (25 with hemangioma, 13 with HEHE, and 19 with HAS) provided hepatic vascular endothelial cell data between June 2006 and May 2017. Results: The proportions of cases with circumscribed margins were 88% (22/25), 84.6% (11/13), and 31.6% (6/19) for hemangioma, HEHE, and HAS, respectively (P < 0.001). HAS lesions were less likely to have circumscribed margins. The proportions of lesions with hemorrhaging were 4% (1/25), 30.8% (4/13), and 36.8% (7/19) for hemangioma, HEHE, and HAS, respectively (P = 0.014). HEHE and HAS cases were more likely to show heterogeneous signals on T1-weighted (T1WI) MRI. HEHE and HAS cases were more likely to show heterogeneous signals on T2-weighted (T2WI) MRI. Centripetal enhancement was the most common pattern in vascular tumors, with proportions of 100, 46.2% (6/13), and 68.4% (13/19) for hemangioma, HEHE, and HAS, respectively. The difference in enhancement pattern between HEHE and HAS was not significant, but rim enhancement was more common for HEHE (46.2%, 6/13). Conclusions: Our study revealed clinical and imaging differences between HEHE and HAS. The platelet count (PLT) and coagulation function of the HAS group decreased, whereas the alpha-fetoprotein (AFP) level increased. The 5-year survival rate for HAS was significantly lower than that of HEHE. A higher malignancy degree indicated a more blurred lesion margin, easier occurrence of hemorrhaging, and more heterogeneous T1WI and T2WI signals.
Background: Lymphovascular invasion (LVI) has never been revealed by preoperative scans. It is necessary to use digital mammography in predicting LVI in patients with breast cancer preoperatively. Methods: Overall 122 cases of invasive ductal carcinoma diagnosed between May 2017 and September 2018 were enrolled and assigned into the LVI positive group (n = 42) and the LVI negative group (n = 80). Independent t-test and χ2 test were performed. Results: Difference in Ki-67 between the two groups was statistically significant (P = 0.012). Differences in interstitial edema (P = 0.013) and skin thickening (P = 0.000) were statistically significant between the two groups. Multiple factor analysis showed that there were three independent risk factors for LVI: interstitial edema (odds ratio [OR] = 12.610; 95% confidence interval [CI]: 1.061-149.922; P = 0.045), blurring of subcutaneous fat (OR = 0.081; 95% CI: 0.012-0.645; P = 0.017) and skin thickening (OR = 9.041; 95% CI: 2.553-32.022; P = 0.001). Conclusions: Interstitial edema, blurring of subcutaneous fat, and skin thickening are independent risk factors for LVI. The specificity of LVI prediction is as high as 98.8% when the three are used together.
Background: A surge in newly diagnosed breast cancer has overwhelmed the public health system worldwide. Joint effort had beed made to discover the genetic mechanism of these disease globally. Accumulated research has revealed autophagy may act as a vital part in the pathogenesis of breast cancer.Objective: Aim to construct a prognostic model based on autophagy-related lncRNAs and investigate their potential mechanisms in breast cancer.Methods: The transcriptome data and clinical information of patients with breast cancer were obtained from The Cancer Genome Atlas (TCGA) database. Autophagy-related genes were obtained from the Human Autophagy Database (HADb). Long non-coding RNAs (lncRNAs) related to autophagy were acquired through the Pearson correlation analysis. Univariate Cox regression analysis as well as the least absolute shrinkage and selection operator (LASSO) regression analysis were used to identify autophagy-related lncRNAs with prognostic value. We constructed a risk scoring model to assess the prognostic significance of the autophagy-related lncRNAs signatures. The nomogram was then established based on the risk score and clinical indicators. Through the calibration curve, the concordance index (C-index) and receiver operating characteristic (ROC) curve analysis were evaluated to obtain the model's predictive performance. Subgroup analysis was performed to evaluate the differential ability of the model. Subsequently, gene set enrichment analysis was conducted to investigate the potential functions of these lncRNAs.Results: We attained 1,164 breast cancer samples from the TCGA database and 231 autophagy-related genes from the HAD database. Through correlation analysis, 179 autophagy-related lncRNAs were finally identified. Univariate Cox regression analysis and LASSO regression analysis further screened 18 prognosis-associated lncRNAs. The risk scoring model was constructed to divide patients into high-risk and low-risk groups. It was found that the low-risk group had better overall survival (OS) than those of the high-risk group. Then, the nomogram model including age, tumor stage, TNM stage and risk score was established. The evaluation index (C-index: 0.78, 3-year OS AUC: 0.813 and 5-year OS AUC: 0.785) showed that the nomogram had excellent predictive power. Subgroup analysis showed there were difference in OS between high-risk and low-risk patients in different subgroups (stage I-II, ER positive, Her-2 negative and non-TNBC subgroups; all P < 0.05). According to the results of gene set enrichment analysis, these lncRNAs were involved in the regulation of multicellular organismal macromolecule metabolic process in multicellular organisms, nucleotide excision repair, oxidative phosphorylation, and TGF-β signaling pathway.Conclusions: We identified 18 autophagy-related lncRNAs with prognostic value in breast cancer, which may regulate tumor growth and progression in multiple ways.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.